United Therapeutics Corporation Asset Resilience Ratio
United Therapeutics Corporation asset resilience ratio. United Therapeutics Corporation (UTHR) has an Asset Resilience Ratio of 11.90% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See UTHR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of United Therapeutics Corporation (1999–2025)
Asset resilience ratio of United Therapeutics Corporation from 1999 to 2025. This chart shows how United Therapeutics Corporation's Asset Resilience Ratio has changed over time. Read UTHR current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down United Therapeutics Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is United Therapeutics Corporation's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $859.10 Million | 11.9% |
| Total Liquid Assets | $859.10 Million | 11.90% |
Asset Resilience Insights
- Moderate Liquidity: United Therapeutics Corporation has 11.90% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
United Therapeutics Corporation Industry Peers by Asset Resilience Ratio
Compare United Therapeutics Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
United Therapeutics Corporation Asset Resilience Ratio by Year (1999–2025)
United Therapeutics Corporation asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for United Therapeutics Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 17.30% | $1.36 Billion | $7.88 Billion | -4.02pp |
| 2024-12-31 | 21.32% | $1.57 Billion | $7.36 Billion | -3.61pp |
| 2023-12-31 | 24.93% | $1.79 Billion | $7.17 Billion | -6.14pp |
| 2022-12-31 | 31.06% | $1.88 Billion | $6.04 Billion | +11.02pp |
| 2021-12-31 | 20.04% | $1.04 Billion | $5.17 Billion | -3.71pp |
| 2020-12-31 | 23.76% | $1.10 Billion | $4.62 Billion | +4.65pp |
| 2019-12-31 | 19.10% | $747.50 Million | $3.91 Billion | -2.85pp |
| 2018-12-31 | 21.96% | $746.70 Million | $3.40 Billion | +14.23pp |
| 2017-12-31 | 7.72% | $222.30 Million | $2.88 Billion | +6.52pp |
| 2016-12-31 | 1.20% | $27.80 Million | $2.33 Billion | -4.39pp |
| 2015-12-31 | 5.58% | $122.00 Million | $2.18 Billion | -10.22pp |
| 2014-12-31 | 15.81% | $297.84 Million | $1.88 Billion | -3.82pp |
| 2013-12-31 | 19.62% | $409.64 Million | $2.09 Billion | -0.37pp |
| 2012-12-31 | 19.99% | $325.18 Million | $1.63 Billion | +4.13pp |
| 2011-12-31 | 15.86% | $240.80 Million | $1.52 Billion | -10.33pp |
| 2010-12-31 | 26.19% | $374.92 Million | $1.43 Billion | +13.91pp |
| 2009-12-31 | 12.28% | $129.14 Million | $1.05 Billion | +0.05pp |
| 2008-12-31 | 12.23% | $106.60 Million | $871.32 Million | -13.44pp |
| 2007-12-31 | 25.68% | $150.73 Million | $587.02 Million | -2.88pp |
| 2006-12-31 | 28.56% | $136.68 Million | $478.55 Million | +9.24pp |
| 2005-12-31 | 19.32% | $56.30 Million | $291.41 Million | +19.22pp |
| 2004-12-31 | 0.10% | $200.00K | $207.16 Million | -17.07pp |
| 2002-12-31 | 17.16% | $31.68 Million | $184.57 Million | +2.23pp |
| 2001-12-31 | 14.93% | $31.68 Million | $212.12 Million | +9.15pp |
| 2000-12-31 | 5.78% | $14.48 Million | $250.64 Million | -49.81pp |
| 1999-12-31 | 55.59% | $33.30 Million | $59.90 Million | -- |
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil)… Read more